Frieling, Helge; Bleich, Stefan
August 2006
European Archives of Psychiatry & Clinical Neuroscience;2006, Vol. 256 Issue 5, p268
Academic Journal
The irreversible inhibitor of monoamine oxidase, tranylcypromine, is a potent antidepressant, but its use is limited to special indications due to side effects and dietary restrictions. The antidepressant action of tranylcypromine is not completely explainable by its effects on monoamine oxidase. Tranylcypromine also leads to an increase in brain trace amines, which are believed to play a key role in the pathophysiology of depression. It also affects other pathophysiological pathways associated with depression. Tranylcypromine treatment leads to an up-regulation of GABAB-receptors and modulates the phospholipid metabolism, which is essential for normal brain function. These findings implicate that the efficacy of tranylcypromine as an antidepressant may be due to its multiple actions within the human brain.


Related Articles

  • tranylcypromine.  // Royal Society of Medicine: Medicines;2002, p542 

    This article presents information on the tranylcypromine which is an antidepressant of the monoamine-oxidase inhibitor class. It has, however, some stimulant effect and so is not as frequently used as some other antidepressants. The method of its administration is oral.

  • tranylcypromine. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p757 

    A definition of the term "tranylcypromine" is presented. Tranylcypromine pertains to a type of antidepressant drug that is also part of the monoamine-oxidase inhibitor (MAOI) group. It is mentioned that the common use of the antidepressant drug is in treating patients suffering from severe...

  • New approaches to antidepressant drug discovery: beyond monoamines. Berton, Olivier; Nestler, Eric J. // Nature Reviews Neuroscience;Feb2006, Vol. 7 Issue 2, p137 

    All available antidepressant medications are based on serendipitous discoveries of the clinical efficacy of two classes of antidepressants more than 50 years ago. These tricyclic and monoamine oxidase inhibitor antidepressants were subsequently found to promote serotonin or noradrenaline...

  • Ten tips for counseling about psychiatric drugs. Tanzi, Maria G. // Pharmacy Today;May2011, Vol. 17 Issue 5, p28 

    The article offers ten tips for counseling on psychiatric drugs thus ensure the safety of patients with psychiatric conditions in the U.S. Close monitoring is required to patients with major depressive disorder and taking antidepressants due to suicidal behavior and thinking. It highlights the...

  • Chapter 3: Breakthroughs in Medicine.  // History of Depression: The Mind-Body Connection;2007, p62 

    Chapter 3 of the book "The History of Depression: The Mind-Body Connection" is presented. It explores the accidental discovery of antidepressant drugs such as monoamine oxidase inhibitors and trycyclics. Iproniazid was developed to treat tuberculosis but was later discovered to be an...

  • Meet the Family: MAOIs.  // History of Depression: The Mind-Body Connection;2007, p67 

    The article presents a list of brand names and generic names of monoamine oxidase inhibitors (MAOI) and tricyclics, families of antidepressants. The antidepressant drug Nardil has a generic name phenelzine sulfate. In the family of tricyclics, the brand anafranil has a generic name clomipramine...

  • A study of refractory cases of depressive illnesses and their response to combined antidepressant treatment. Sethna, E. R. // British Journal of Psychiatry;Mar74, Vol. 124, p265 

    The article presents a study on refractory cases of depressive illnesses and their response to combined antidepressant treatment. The authors' opinions differ on the effectiveness and the risk involved in treating depressive illnesses with combinations of monoamine oxidase inhibitors and...

  • Clinical: Clinical Q&A - Antidepressants and ACE inhibitors. Anderson, Ian; Bain, Steve // GP: General Practitioner;3/3/2006, p54 

    The article presents experts' advice on antidepressants and angiotensin converting enzyme (ACE) inhibitors. When changing from a tricyclic antidepressant to an SSRI, the key point to remember is that some SSRIs interfere with tricyclic metabolism and may increase plasma concentrations. It is...

  • New Therapeutic Strategy for Mood Disorders. Crupi, R.; Marino, A.; Cuzzocrea, S. // Current Medicinal Chemistry;Oct2011, Vol. 18 Issue 28, p4284 

    The development of new treatments for mood disorders, as anxiety and depression, is based on identification of neural substrates and the mechanisms underlying their etiology and pathophysiology. The heterogeneity of mood disorders indicates that its origin may lie in dysfunction of multiple...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics